This Medical Product Alert relates to confirmed falsified versions of ICLUSIG 45mg circulating in the WHO Region of the Western Pacific. This is linked to the WHO Medical Product Alert N°2/2019 issued on 31 January 2019 regarding falsified ICLUSIG traded globally.
Genuine ICLUSIG, the active pharmaceutical ingredient of which is Ponatinib Hydrochloride, is used to treat different forms of leukaemia.
On 18 February 2019, WHO was informed that a wholesaler based in Malaysia had purchased the product ICLUSIG 45mg with batch number PR072875, presented in English language packaging. This specific product is referenced in the previous
WHO Medical Product Alert N°2/2019 and is confirmed falsified.